Abstract:Abstract Prostate cancer (PCa) is the second-leading cause of cancer mortalities and morbidities in the United States and is the most commonly diagnosed malignancy in men. Despite the fact that androgen deprivation therapy is the first-line option to initial responses, most PCa patients invariably develop castration-resistant prostate cancer (CRPC). CRPC is a lethal type of malignancy, therefore, novel and effective treatment strategies are needed. The goal of this study was to evaluate the combination treatment of small molecule inhibitors, SZL-P1-41, a SKP2 target and PBIT, a KDM5B target on PCa growth and progression; as well as to delineate the underlying mechanisms of suppressing CRPC. Literature reports that S-Phase Kinase Associated Protein 2 (SKP2) is upregulated in PCa and Lysine-specific demethylase 5B (KDM5B) serves as a histone demethylase with a crucial role in cancers. Studies showed that KDM5B is increased in human PCa and KDM5B knockout decreases carcinogenic properties of PCa cells. We previously reported that SKP2 loss partially decreases the growth of prostate tumors and that KDM5B levels are reversely regulated by SKP2 in PCa cells. However, the mechanisms of KDM5B and SKP2 interplay on PCa malignancy is unknown. We hypothesize that combination of PBIT and SZL-P1-41 treatment will enhance anti-cancer effects on PCa progression by inducing cellular senescence. Here, we showed that inhibition of KDM5B and SKP2 decreased the proliferation of PCa cells, and KDM5B KO cells were more vulnerable to SKP2 inhibition. More importantly, a combined inhibition of KDM5B and SKP2 significantly blocked malignant progression and migration of PCa cells. Mechanistically, combined inhibition of KDM5B and SKP2 in PCa cells abrogated AKT activation, resulting in an induction of cellular senescence, which was measured via Western blot analysis and senescence-associated β-galactosidase (SA-β-Gal) staining. Taken together, our results show that combined inhibition of KDM5B and SKP2 is more efficacious in inhibiting proliferation and migration in CRPC cells, and this regimen would be an ideal therapeutic approach for treating CRPC. Citation Format: LaKendria K. Brown, Thanigaivelan Kanagasabai, Guoliang Li, Sherly I. Celada, Zhenbang Chen. Combination targeting of SKP2 and KDM5B induces senescence in castration-resistant prostate cancer cells via AKT signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7270.

IKK Inhibitor Suppresses Epithelial-Mesenchymal Transition and Induces Cell Death in Prostate Cancer.

Nkx3.1 and P27kip1cooperate in Proliferation Inhibition and Apoptosis Induction in Human Androgen–Independent Prostate Cancer Cells

DAB2IP Coordinates Both PI3K-Akt and ASK1 Pathways for Cell Survival and Apoptosis

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

Expression of Nkx3.1 Enhances 17 Beta-Estradiol Anti-Tumor Action in PC3 Human Prostate Cancer Cells

Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability

Tumor-suppressive Microrna-497 Targets IKKβ to Regulate NF-κB Signaling Pathway in Human Prostate Cancer Cells.

Targeted Inhibition of Mtor by BML-275 Induces Mitochondrial-Mediated Apoptosis and Autophagy in Prostate Cancer.

Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer

Integrin-linked Kinase Overexpression Promotes Epithelial-Mesenchymal Transition Via Nuclear Factor-Κb Signaling in Colorectal Cancer Cells.

Aphthous Ulcer Drug Inhibits Prostate Tumor Metastasis by Targeting IKKɛ/TBK1/NF-κB Signaling

Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer

CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation

Co‐targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Effects of calcium/calmodulin dependent protein kinase Ⅱ on proliferation, invasion and epithelia-mesenchymal transition of prostate cancer PC3 cells

Abstract 7270: Combination targeting of SKP2 and KDM5B induces senescence in castration-resistant prostate cancer cells via AKT signaling

HDAC Inhibition Impedes Epithelial–mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer

MIIP Inhibits EMT and Cell Invasion in Prostate Cancer Through Mir-181A/b-5p-klf17 Axis.

MP62-19 AKR1C3 OVEREXPRESSION IN PROSTATE CANCER PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND METASTASIS VIA ACTIVATION OF MAPK/ERK SIGNALING AND UPREGULATION OF ZEB1

In vitro and in vivo effects of short hairpin RNA targeting integrin-linked kinase in prostate cancer cells.